Letrozole Treatment in Idiopathic Peripheral Precocious Puberty Without Diagnosis of McCune-Albright Syndrome: A Case Report.

J Pediatr Adolesc GynecolMay 9, 2026 (epub)
Case ReportPediatricsEndocrinology

Carlotta Tartarini, Eugenio Trinati, Gaia Varriale et al.

✦ AI-curated · Sources linked

Case in brief

A girl with idiopathic peripheral precocious puberty presented with premature thelarche, recurrent vaginal bleeding, and elevated estradiol levels, alongside ultrasound findings of ovarian cysts. After excluding McCune-Albright syndrome through comprehensive evaluation, she was treated with off-label letrozole. The treatment resulted in regression of uterine maturation and ovarian cysts, normalization of blood tests, and cessation of vaginal bleeding without adverse effects.

Diagnostic / clinical pearl

Letrozole may be an effective treatment for idiopathic peripheral precocious puberty when McCune-Albright syndrome is excluded.

Source

PubMed · PMID 42114591

Published in J Pediatr Adolesc Gynecol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.